Matinas Biopharma (NYSEAMERICAN:MTNB) Releases Quarterly Earnings Results

Matinas Biopharma (NYSEAMERICAN:MTNB) posted its earnings results on Tuesday. The company reported ($0.26) earnings per share (EPS) for the quarter, FiscalAI reports.

Matinas Biopharma Stock Up 4.2%

MTNB stock traded up $0.02 during mid-day trading on Wednesday, reaching $0.52. 5,272 shares of the stock traded hands, compared to its average volume of 28,323. The firm has a market capitalization of $3.34 million, a PE ratio of -0.15 and a beta of 1.32. The business has a 50-day moving average of $0.61 and a two-hundred day moving average of $0.98. Matinas Biopharma has a 52 week low of $0.47 and a 52 week high of $3.09.

Hedge Funds Weigh In On Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC bought a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma as of its most recent SEC filing. Hedge funds and other institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.